How to ensure the quality and safety of unlicensed oral medicines

Pharmaceutical Journal

Volumn 281, Issue 7517, 2008, Pages 240-243

  Lowey, Andrew ^a   Jackson, Mark ^a  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; RAMIPRIL; SACCHARIN; SORBITOL; XANTHAN;

ARTICLE; DOSE CALCULATION; DRUG APPROVAL; DRUG DEGRADATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; DRUG STABILITY; DRUG SURVEILLANCE PROGRAM; HUMAN; NATIONAL HEALTH SERVICE; NONHUMAN; PHYSICAL CHEMISTRY; PROFESSIONAL COMPETENCE; PROFESSIONAL PRACTICE; RISK ASSESSMENT; SHELF LIFE;

EID: 52149109515     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Gill AM, Leach HJ, Hughes J, Barker C, Nunn AJ, Choonara I. Adverse drug reactions in a paediatric intensive care unit. Acta Paediatric 1995;84:438-41.
2. Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: prospective study. Acta Paediatric 1999;88:965-8.
3. Marshall IW, Daly MJ. Risk management in hospital pharmacy. Pharmacy Management 1996;12:44-47.
4. Baby dies after peppermint water prescription for colic. The Pharmaceutical Journal 1998;260:768.
5. Kaye T. The quandary of compounding for MCOs: administrative costs, risks, and waste. Managed Care 2003;(Jan):42-46.
6. Kirsch L. Extemporaneous quality. Journal of Pharmaceutical Science and Technology 2005;59:1-2.
7. Stewart PJ, Tucker IG. A survey of current extemporaneously prepared paediatric formulations. Australian Journal of Hospital Pharmacy 1982;12:64-68.
8. Crawford SY, Dombruwski SR. Extemporaneous compounding activities and the associated needs of pharmacists. American Journal of Hospital Pharmacy 1991;48:1205-10.
9. Woods DJ. Extemporaneous formulations - problems and solutions. Paediatric Perinatal Drug Therapy 1997;1:25-29.
10. Fisher CM, Corrigan OI, Henman MC. Quality of pharmaceutical services in community pharmacies. Journal of Social and Administrative Pharmacy 1991;8:175-6.
11. Davis NM. Do you really need glacial acetic acid on your shelf? Hospital Pharmacy 1997;32:611.
12. Standards for good professional practice: Council sets standards for extemporaneous dispensing. The Pharmaceutical Journal 2000;265:233.
13. Royal Pharmaceutical Society. Medicines, ethics and practice: a guide for pharmacists and pharmacy technicians. London: The Society; 2007.
14. Fenton-May V, editor. Guide to the preparation of non-sterile extemporaneous products in NHS hospitals. NHS Quality Assurance Committee; 2003.
15. Pappas A, McPherson R, Stewart K. Extemporaneous dispensing: whatever happened to it? A survey of Australian general practitioners. Journal of Pharmaceutical Research. 2002;32:310-14.
16. Chowdury T, Taylor KMG, Harding G. Teaching of extemporaneous preparation in UK schools of pharmacy. Pharmaceutical Education 2003;3:229-36.
17. Neill H. Do not be afraid to ask for help (letter). The Pharmaceutical Journal 2003;270:266.
18. Mulla H, Tofeig M, Bi'Lock B, Samani N, Pandya HC. Variations in captopril formulations used to treat children with heart failure: a survey in the United Kingdom. Archive of Disease in Childhood 2007;92:409-11.
19. British Pharmacopoeia 2007. London: The Stationery Office.
20. Sweetman SC, editors. Martindale: The Complete Drug Reference, 34th edition. London: The Pharmaceutical Press;2005
21. Kadin H. Captopril. In: Florey K, editor. Analytical profiles of drug substances. London: Academic Press; 1982. vol 11: pp79-137.
22. Rusho WJ. Clinical issues and concerns in the use of extemporaneously compounded medications. Journal of Pharmaceutical Care in Pain Symptom Control 1996;4:5-20.
23. Hanson G. Bespoke pharmacy: tailoring medicines to the needs of patients - the pharmacy production unit's role. Hospital Pharmacy 2003;10:155-159.
24. Shipkowski ER. In: Kadin H. Captopril. In: Florey K, editor. Analytical profiles of drug substances. London: Academic Press; 1982. vol 11: pp79-137.
25. Chen D, Chen H, Ku H. Degradation of captopril in aqueous medium through buffer-catalysis oxidation. Drug Development in Industrial Pharmacy 1995:21:781-792.
26. Connors KA, Amidon GL, Stella ZI. Chemical stability of pharmaceuticals: a handbook for pharmacists, 2nd ed. 1986.
27. Wang YJ. In: Kadin H. Captopril. In: Florey K, editor. Analytical profiles of drug substances. London: Academic Press;1982. vol 11: pp79-137.
28. Pereira CM, Tam YK. Stability of captopril in tap water. The Pharmaceutical Journal 1992;49:612-5.
29. Pramar Y, Das Gupta V, Bethea C. Stability of captopril in some aqueous systems. Journal of Clinical Pharmacology and Therapeutics 1992;17:185-9.
30. Anaizi NH, Swenson C. Instability of aqueous captopril solutions. American Journal of Hospital Pharmacy 1993;50:486-8.
31. Escribano-Garcia MJ, Torrado-Duran S, Torrado-Duran JJ. Stability study of an aqueous formulation of captopril at 1mg/ml. Farm Hospital 2005;29:30-36.
32. Andrews CD, Essex A. Captopril suspension (letter). The Pharmaceutical Journal 1986;237:734-5.
33. Nahata MC, Morosco R, Hipple TF. Stability of captopril in three liquid dosage forms. American Journal of Hospital Pharmacy 1994;51:95-96.
34. Schlatter J, Sola A, Saulnier JL. Stabilite d'une solution orale de captopril 1mg/ml. Journal de Pharmacie Clinique 1997;16(2):125-8.
35. Berger-Gryllaki M, Podilsky G, Widmer N, Gloor S, Testa B, Pannatier A. The development of a stable oral solution of captopril for paediatric patients. EJHP Science 2007;13:67-72.
36. Chan DS, Sato AK, Claybaugh JR. Degradation of captopril in solutions compounded from tablets and standard powder. American Journal of Hospital Pharmacy 1994;51:1205-7.
37. Liu J, Chan SY, Ho PC. Effects of sucrose, citric buffer and glucose oxidase on the stability of captopril in liquid formulations. Journal of Clinical Pharmacy and Therapeutics 1999;24:145-50.
38. Lye MYF, Yow KL, Lim LY, Chan SY, Chan E, Ho PC. Effects of ingredients on stability of captopril in extemporaneously prepared oral liquids. American Journal of Health-System Pharmacy 1997;54:2483-7.
39. Allen LV Jr, Erickson MA. Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids. American Journal of Health-System Pharmacy 1996;53:2179-84.
40. CHIP3 Regulations. Chemicals (Hazard Information and Packaging for Supply) Regulations, 2002.
41. Council on Scientific Affairs. Saccharin: review of safety issues. Journal of American Medical Association 1985;254:2622-2624.
42. Morgan RW, Wong O. A review of epidemiological studies on artificial sweeteners and bladder cancer. Food and Chemical Toxicology 1985;23:529-533.
43. Brown AM, Masson E. "Hidden" sorbitol in proprietary medicines - a cause for concern? The Pharmaceutical Journal 1990;245:211.
44. Greaves RRSH, Brown RL, Farthing MJG. An air stewardess with puzzling diarrhoea. Lancet 1996;348:1488.
45. Mathew M, Das Gupta V. The stability of captopril in aqueous systems. Drug Stability 1996;1:161-5.
46. NHS Pharmaceutical Quality Assurance Committee. Guidance for the purchase and supply of unlicensed medicinal products - notes fur prescribers and pharmacists. 3rd edition. 2004.